| Symbol | APRE |
|---|---|
| Name | APREA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 535 BOYLSTON STREET, BOSTON, Massachusetts, 02116, United States |
| Telephone | +1 617 463-9385 |
| Fax | — |
| — | |
| Website | https://www.aprea.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001781983 |
| Description | Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Additional info from NASDAQ: |
Director Grissinger Michael 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075286
Read moreDirector Gruia Gabriela 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075284
Read moreDirector Peters Richard 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075283
Read moreDirector HENNEMAN JOHN B III 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075282
Read moreDirector BIZZARI JEAN-PIERRE 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075281
Read moreDirector Duey Marc 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075280
Read moreDirector Pamukcu Rifat 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075279
Read moreDirector Seizinger Bernd R. 🟢 acquired 15.7K shares (1 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.73 Transaction Date: Jun 16, 2026 | Filing ID: 075278
Read more(99% Neutral) APREA THERAPEUTICS, INC. (APRE) Announces Regulatory Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectabl… | Phase1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Not_Yet_Recruiting | 2026-08-31 | 2030-08-31 | ClinicalTrials.gov |
| NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Hi… | Phase1 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2026-08-31 | 2031-12-31 | ClinicalTrials.gov |
| NCT06260514 | Study of APR-1051 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2024-06-13 | 2028-06-01 | ClinicalTrials.gov |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2023-01-09 | 2028-02-01 | ClinicalTrials.gov |
| NCT04638309 | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplast… | Phase1 | MDS | Terminated | 2021-09-20 | 2022-04-25 | ClinicalTrials.gov |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjec… | Phase1 | Non Hodgkin Lymphoma | Terminated | 2021-03-02 | 2021-08-24 | ClinicalTrials.gov |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With S… | Phase1 | Bladder Cancer | Completed | 2020-06-25 | 2022-04-30 | ClinicalTrials.gov |
| NCT04214860 | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid M… | Phase1 | Myeloid Malignancy | Completed | 2019-12-13 | 2022-01-14 | ClinicalTrials.gov |
| NCT03931291 | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leu… | Phase2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | Completed | 2019-09-16 | 2022-01-14 | ClinicalTrials.gov |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndrome… | Phase3 | MDS | Completed | 2019-01-11 | 2022-01-14 | ClinicalTrials.gov |
| NCT03588078 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | Phase1 | Myelodysplastic Syndrome With Gene Mutation | Unknown | 2018-09-15 | 2021-05-15 | ClinicalTrials.gov |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BR… | Phase1 | Melanoma | Terminated | 2018-01-18 | 2018-08-08 | ClinicalTrials.gov |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study … | Phase2 | High-grade Serous Ovarian Cancer | Completed | 2017-07-31 | 2019-07-10 | ClinicalTrials.gov |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant M… | Phase1 | Myelodysplastic Syndrome | Completed | 2017-05-18 | 2021-12-08 | ClinicalTrials.gov |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phas… | Phase1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | Completed | 2014-03-01 | 2019-04-01 | ClinicalTrials.gov |
| NCT00900614 | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prost… | Phase1 | Hematologic Neoplasms | Completed | 2009-05-01 | 2010-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07617363 |
| ATRN-119 | Other | Phase PHASE1 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT07617363 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Stereotactic Body Radiation Therapy (SBRT) | Drug | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| ATRN-119 | Other | Phase PHASE1 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07578467 |
| Dabrafenib | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| APR-246 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndrome With Gene Mutation | UNKNOWN | NCT03588078 |
| APR-246 | Other | Phase PHASE1 | Myelodysplastic Syndrome With Gene Mutation | UNKNOWN | NCT03588078 |
| Azacitidine | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT03072043 |
| APR-246 | Other | Phase PHASE1 | Myelodysplastic Syndrome | COMPLETED | NCT03072043 |
| APR-548 + Azacitidine | Other | Phase PHASE1 | MDS | TERMINATED | NCT04638309 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Acalabrutinib in CLL | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| Azacitidine | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| Venetoclax | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 | Other | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 | Other | Phase PHASE2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | COMPLETED | NCT03931291 |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Other | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| APR-246 | Other | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Other | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| APR-246 | Other | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| Azacitidine | Other | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| APR-246 + azacitidine | Other | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| APR-246 (eprenetapopt) + Pembrolizumab | Other | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT04383938 |
| ATRN-119 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04905914 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| APR-1051 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06260514 |
| ATRN-119 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04905914 |
| APR-548 + Azacitidine | DRUG | Phase PHASE1 | MDS | TERMINATED | NCT04638309 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Acalabrutinib in CLL | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT04419389 |
| APR-246 (eprenetapopt) + Pembrolizumab | DRUG | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT04383938 |
| Venetoclax | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| APR-246 + azacitidine | DRUG | Phase PHASE3 | MDS | COMPLETED | NCT03745716 |
| Dabrafenib | DRUG | Phase PHASE1 | Melanoma | TERMINATED | NCT03391050 |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | DRUG | Phase PHASE2 | High-grade Serous Ovarian Cancer | COMPLETED | NCT03268382 |
| Azacitidine | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | DRUG | Phase PHASE1 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | COMPLETED | NCT02098343 |
| APR-246 | DRUG | Phase PHASE1 | Myeloid Malignancy | COMPLETED | NCT04214860 |